Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Funafuti Tech Report.
Press releases published on July 30, 2025
Viomi Technology Co., Ltd Granted Exception by Nasdaq Staff Regarding Form 20-F Filing
GlobeNewswire
·
July 30, 2025
GUANGZHOU, China, July 30, 2025 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd (“Viomi” or the “Company”) (NASDAQ: VIOT), a leading technology company for home water solutions in China, today announced that it has been granted an exception by the Nasdaq …
Check Point Software Reports 2025 Second Quarter Financial Results
GlobeNewswire
·
July 30, 2025
TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Check Point® Software Technologies Ltd. (NASDAQ: CHKP), today announced its financial results for the quarter ended June 30th, 2025. Second Quarter 2025 Financial Highlights: Total Revenues: $665 million, …
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
GlobeNewswire
·
July 30, 2025
License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the oral GLP-1, SYH2086, offers potential for a best-in- …
Aurora Mobile’s GPTBots.ai to Integrate Zhipu AI’s Flagship GLM-4.5 Model to Enhance AI Capabilities
GlobeNewswire
·
July 30, 2025
SHENZHEN, China, July 30, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that its AI agent platform, …
Dr. Falk Pharma und Allianthera (Suzhou) Biopharmaceuticals gehen strategische Partnerschaft für die Entwicklung eines neuartigen AhR-Agonisten ein
GlobeNewswire
·
July 30, 2025
Freiburg (Deutschland), Suzhou (China) und Boston (USA), 30. Juli 2025: Dr. Falk Pharma GmbH und Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. geben strategische Partnerschaft für die Entwicklung eines neuartigen AhR-Agonisten zur Behandlung …
Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development
GlobeNewswire
·
July 30, 2025
Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the Treatment of Moderate to Severe Ulcerative …
New cside Report Shows Surge in Browser-Side Security Threats: Over 72,000 Websites Compromised in Q2 2025
GlobeNewswire
·
July 30, 2025
Client-side attacks are rapidly evolving, ranging from OAuth abuse to crypto wallet drainers WordPress and mobile browsers have been the primary targets Compliance risks are mounting under GDPR, PCI DSS 4.0.1, and CCPA SAN FRANCISCO, July 30, 2025 (GLOBE …
Atos reconnu Supplier Engagement Leader par le CDP pour la 5ème fois
GlobeNewswire
·
July 30, 2025
Communiqué de presse Atos reconnu Supplier Engagement Leader par le CDP pour la 5ème fois Paris, France – 30 juillet 2025 – Atos intègre, pour la 5ème fois, le prestigieux classement Supplier Engagement Rating …
Atos recognized as Supplier Engagement Leader by CDP for the 5th time
GlobeNewswire
·
July 30, 2025
Press Release Atos recognized as Supplier Engagement Leader by CDP for the 5th time Paris, France – July 30, 2025 – Atos has been recognized for the fifth time by the Carbon Disclosure …
Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre
GlobeNewswire
·
July 30, 2025
VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, is pleased to …
SoulGen Debuts AI-Powered Image-to-Video Platform, Ushering in a New Era of Ultra-Fast, Character-Consistent Visual Content
GlobeNewswire
·
July 30, 2025
HONG KONG, July 30, 2025 (GLOBE NEWSWIRE) -- SoulGen, a frontier innovator in artificial intelligence media solutions, has officially released its much-anticipated AI platform that converts still images into vivid, high-resolution video clips. This release …
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
GlobeNewswire
·
July 30, 2025
PRESS RELEASE AB SCIENCE RECEIVES REGULATORY APPROVAL FROM EUROPEAN COUNTRIES TO INITIATE THIRD STAGE OF PHASE I/II STUDY COMBINING ITS MOLECULE AB8939 WITH VENETOCLAX FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA THE COMBINATION OF AB8939 TARGETING …
AB Science a reçu l’approbation règlementaire de pays européens pour initier la troisième étape de la phase I/II visant à combiner sa molécule AB8939 avec le venetoclax dans le traitement de la LMA
GlobeNewswire
·
July 30, 2025
COMMUNIQUÉ DE PRESSE AB SCIENCE A RECU L’APPROBATION REGLEMENTAIRE DE PAYS EUROPEENS POUR INITIER LA TROISIEME ETAPE DE LA PHASE I/II VISANT A COMBINER SA MOLÉCULE AB8939 AVEC LE VENETOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË LA COMBINAISON D’ …
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
GlobeNewswire
·
July 30, 2025
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years …
Communiqué de presse: Le SAR446523 de Sanofi, un anticorps monoclonal anti-GPRC5D, se voit accorder la désignation médicament orphelin pour le myélome multiple aux États-Unis
GlobeNewswire
·
July 30, 2025
Le SAR446523 de Sanofi, un anticorps monoclonal anti-GPRC5D, se voit accorder la désignation médicament orphelin pour le myélome multiple aux États-Unis Désignation accordée pour l’anticorps monoclonal GPRC5D à base d’immunoglobulines G pour le traitement …
Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
GlobeNewswire
·
July 30, 2025
Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment of patients with relapsed or refractory multiple …
En respuesta al Plan de Acción sobre IA de la Casa Blanca, ZenaDrone de ZenaTech lanza Zena AI, Inc., un centro especializado de desarrollo de inteligencia artificial para aplicaciones de defensa y seguridad nacional en Estados Unidos
GlobeNewswire
·
July 30, 2025
VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), un proveedor de soluciones tecnológicas empresariales especializado en drones con inteligencia artificial (IA), Dron como un …
Larimar Therapeutics Announces Pricing of Underwritten Public Offering
GlobeNewswire
·
July 30, 2025
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously …
QCI Posts 50% Organic Growth Over Prior Year; Accelerated Global Expansion Across Australia and Asia and Acquisition of VizExplorer Set to Drive Further Gains
GlobeNewswire
·
July 30, 2025
SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Quick Custom Intelligence (QCI), the global leader in AI and analytics for the casino industry, today announced a 50% organic growth through June 2025 compared to the prior 12 months, underscoring the company’s …